Kristina M. Jordahl

Kristina M. Jordahl

Auto-generated profile, based on publicly available information

Kristina M. Jordahl

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Cancer Research
Verified
Journal Article
Open access
EAElom Kouassivi Aglago
Elom Kouassivi Aglago
AKAndre Kim
Andre Kim
YLYi Lin
Yi Lin
CQConghui Qu
Conghui Qu
MEMarina Evangelou
Marina Evangelou
PCPeter T. Campbell
Peter T. Campbell
Colorectal cancer risk can be impacted by genetic, environmental, and lifestyle factors, including diet and obesity. Gene-environment interactions (G × E) can provide biological insights into the effects of obesity on colorectal cancer risk. Here, we assessed potential genome-wide G × E interactions between body mass index (BMI) and common SNPs for colorectal cancer risk using data from 36,415 colorectal cancer cases and 48,451 controls from three international colorectal cancer consortia (CCFR, CORECT, and GECCO). The G × E tests included the conventional logistic regression using multiplicative terms (one degree of freedom, 1DF test), the two-step EDGE method, and the joint 3DF test, each of which is powerful for detecting G × E interactions under specific conditions. BMI was associated with higher colorectal cancer risk. The two-step approach revealed a statistically significant G×BMI interaction located within the Formin 1/Gremlin 1 (FMN1/GREM1) gene region (rs58349661). This SNP was also identified by the 3DF test, with a suggestive statistical significance in the 1DF test. Among participants with the CC genotype of rs58349661, overweight and obesity categories were associated with higher colorectal cancer risk, whereas null associations were observed across BMI categories in those with the TT genotype. Using data from three large international consortia, this study discovered a locus in the FMN1/GREM1 gene region that interacts with BMI on the association with colorectal cancer risk. Further studies should examine the potential mechanisms through which this locus modifies the etiologic link between obesity and colorectal cancer. Significance: This gene-environment interaction analysis revealed a genetic locus in FMN1/GREM1 that interacts with body mass index in colorectal cancer risk, suggesting potential implications for precision prevention strategies.

30 March 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JDJames Y Dai
James Y Dai
XWXiaoyu Wang
Xiaoyu Wang
BWBo Wang
Bo Wang
WSWei Sun
Wei Sun
KJKristina M Jordahl
Kristina M Jordahl
JSJanet L Stanford
Janet L Stanford
Genome-wide association studies have identified more than 100 SNPs that increase the risk of prostate cancer (PrCa). We identify and compare expression quantitative trait loci (eQTLs) and CpG methylation quantitative trait loci (meQTLs) among 147 established PrCa risk SNPs in primary prostate tumors (n = 355 from a Seattle-based study and n = 495 from The Cancer Genome Atlas, TCGA) and tumor-adjacent, histologically benign samples (n = 471 from a Mayo Clinic study). The role of DNA methylation in eQTL regulation of gene expression was investigated by data triangulation using several causal inference approaches, including a proposed adaptation of the Causal Inference Test (CIT) for causal direction. Comparing eQTLs between tumors and benign samples, we show that 98 of the 147 risk SNPs were identified as eQTLs in the tumor-adjacent benign samples, and almost all 33 eQTL identified in tumor sets were also eQTLs in the benign samples. Three lines of results support the causal role of DNA methylation. First, nearly 100 of the 147 risk SNPs were identified as meQTLs in one tumor set, and almost all eQTLs in tumors were meQTLs. Second, the loss of eQTLs in tumors relative to benign samples was associated with altered DNA methylation. Third, among risk SNPs identified as both eQTLs and meQTLs, mediation analyses suggest that over two-thirds have evidence of a causal role for DNA methylation, mostly mediating genetic influence on gene expression. In summary, we provide a comprehensive catalog of eQTLs, meQTLs and putative cancer genes for known PrCa risk SNPs. We observe that a substantial portion of germline eQTL regulatory mechanisms are maintained in the tumor development, despite that somatic alterations in tumor genome. Finally, our mediation analyses illuminate the likely intermediary role of CpG methylation in eQTL regulation of gene expression. We conduct rigorous eQTL and meQTL mapping for the 147 confirmed PrCa risk SNPs using comprehensive genomic data in primary prostate tumors (TCGA and FHCRC) and tumor-adjacent benign samples (Mayo Clinic). The goal is to explore the biological mechanisms of how SNPs predispose to PrCa risk, and to investigate the causal role of DNA methylation in genetic regulation of gene expression. To our knowledge this is the first eQTL study for PrCa risk SNPs that includes the comparison between tumors and benign samples, as well as studying DNA methylation. We use several causal inference approaches, including a proposed adaptation of the Causal Inference Test (CIT) to decipher the direction of causality. We provide a comprehensive catalog of eQTLs, meQTLs and putative cancer genes for known PrCa risk SNPs, which shows eQTL regulatory mechanisms largely maintained in prostate tumors, and our mediation analyses shed light on the intermediary role of CpG methylation in eQTL regulation of gene expression.

24 February 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
KJKristina M. Jordahl
Kristina M. Jordahl
ASAnna Shcherbina
Anna Shcherbina
AKAndre E. Kim
Andre E. Kim
YSYu-Ru Su
Yu-Ru Su
YLYi Lin
Yi Lin
UPUlrike Peters
Ulrike Peters
Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r2 > 0.9 in the 10q24.2/COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.

18 April 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
XWXiaoyu Wang
Xiaoyu Wang
KJKristina M. Jordahl
Kristina M. Jordahl
CZChenghao Zhu
Chenghao Zhu
JLJulie Livingstone
Julie Livingstone
SRSuhn Kyong Rhie
Suhn Kyong Rhie
JDJames Y. Dai
James Y. Dai
Background: Patients with prostate cancer experience heterogeneous outcomes after radical prostatectomy. Genomic studies including The Cancer Genome Atlas (TCGA) have reported molecular signatures of prostate cancer, but few studies have assessed the prognostic effects of DNA methylation profiles. Methods: We conducted the largest methylome subtyping analysis for primary prostate tumors to date, using methylome data from three patient populations: TCGA, a prostate cancer cohort study conducted at the Fred Hutchinson Cancer Research Center (FH; Seattle, WA), and the Canadian International Cancer Genome Consortium (ICGC) cohort. Four subtypes were detected in the TCGA dataset, then independently assigned to FH and ICGC cohort data. The identified methylation subtypes were assessed for association with cancer prognosis in the above three patient populations. Results: Using a set of hypermethylated CpG sites, four methylation subtypes were identified in TCGA. Compared with subtype 1, subtype 4 had an HR of 2.09 (P = 0.029) for biochemical recurrence (BCR) in TCGA patients. HRs of 2.76 (P = 0.002) for recurrence and 9.73 (P = 0.002) for metastatic-lethal (metastasis or prostate cancer–specific death) outcomes were observed in the FH cohort. A similar pattern of association was noted in the Canadian ICGC cohort, though HRs were not statistically significant. Conclusions: A hypermethylated subtype was associated with an increased hazard of recurrence and mortality in three studies with prostate tumor methylome data. Further molecular work is needed to understand the effect of methylation subtypes on cancer prognosis. Impact: This study identified a DNA methylation subtype that was associated with worse prostate cancer prognosis after radical prostatectomy.

2 June 2026 in Blood
Verified
Journal Article
Open access
SBSusan Bal
Susan Bal
MHMyo Htut
Myo Htut
ONOmar Nadeem
Omar Nadeem
LALarry D. Anderson
Larry D. Anderson
TGTara Gregory
Tara Gregory
JBJesus G Berdeja
Jesus G Berdeja
Patients with relapsed/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel, BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). This phase 1, dose-escalation/expansion study (NCT04674813) enrolled adult patients with RRMM and ≥3 prior antimyeloma treatment regimens, including an immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody. At baseline, patients (N=84) had a median of 5 prior regimens and 49% had previously received BCMA-targeted therapy, of whom 38% received CAR T-cell therapy. Arlo-cel was administered as a one-time intravenous infusion of 25×106-450×106 CAR T cells. Primary endpoints were safety and maximum tolerated dose (MTD); secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Data cutoff was 23August2024. Cytokine release syndrome (CRS) occurred in 82% of patients, immune effector cell-associated neurotoxicity syndrome in 10%, and other select neurotoxicities in 12%; most were grade 1/2 and frequency appeared dose-dependent. One death occurred from CRS at highest dose level. On-target/off-tumor skin (30%), nail (19%), and oral (32%) adverse events were transient, grade 1/2; most resolved without intervention. MTD was not reached. With median follow-up of 16.1 months, ORR=87% (complete response rate=53%), median duration of response=18.0 months, and median PFS=18.3 months (95% CI, 11.8-21.9) (n=79). The 1-year OS rate was 90% (N=84). In conclusion, arlo-cel had a safety profile supportive of future study and demonstrated deep and durable responses, with promising PFS and OS in patients with heavily pretreated RRMM.

31 May 2024 in Science Advances
Verified
Journal Article
Open access
DDDavid A. Drew
David A. Drew
AKAndre E. Kim
Andre E. Kim
YLYi Lin
Yi Lin
CQConghui Qu
Conghui Qu
JMJohn Morrison
John Morrison
WGW. James Gauderman
W. James Gauderman
Regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on colorectal cancer (CRC) risk. We leveraged pooled data from 52 clinical trial, cohort, and case-control studies that included 30,806 CRC cases and 41,861 controls of European ancestry to conduct a genome-wide interaction scan between regular aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and imputed genetic variants. After adjusting for multiple comparisons, we identified statistically significant interactions between regular aspirin/NSAID use and variants in 6q24.1 (top hit rs72833769 ), which has evidence of influencing expression of TBC1D7 (a subunit of the TSC1-TSC2 complex, a key regulator of MTOR activity), and variants in 5p13.1 (top hit rs350047 ), which is associated with expression of PTGER4 (codes a cell surface receptor directly involved in the mode of action of aspirin). Genetic variants with functional impact may modulate the chemopreventive effect of regular aspirin use, and our study identifies putative previously unidentified targets for additional mechanistic interrogation.